1) Burosumab for treating X-linked hypophosphataemia (ID1151) NICE Final Evaluation Document, Septiembre de 2018 https://www.nice.org.uk/guidance/indevelopment/gid-hst10016 /documents 2) Crysvita (burosumab) Summary of Product Characteristics (SmPC) http://www.ema.europa.eu/ema/index.jsp?c... 3) Carpenter T, Whyte M, Imel E et al. Burosumab therapy in children with X-linked hypophosphataemia. N Engl J 2018; 378(21):1987-1998
CONTACTO: Relaciones con los medios: Callum Spreng,callum@sprengthomson.com, 07803-970103; Public Affairs: Yvette Venable,yvette.venable@kyowakirin.com, 07388-222769
